# 5. Status Epilepticus Protocol

[← Previous: Special Populations](04-special-populations.md) | [Back to Main](../README.md) | [Next: Drug Interactions →](06-drug-interactions.md)

---

## 5.1 Definition

| Term | Definition |
|------|------------|
| **Status Epilepticus (SE)** | Seizure lasting >5 minutes OR ≥2 seizures without full recovery between |
| **Refractory SE** | Continues despite first-line and second-line treatment |
| **Super-refractory SE** | Continues ≥24 hours after anesthetic treatment initiation |

---

## 5.2 Treatment Algorithm

```
TIME 0-5 MIN: STABILIZATION
├── ABCs (Airway, Breathing, Circulation)
├── IV access, O2, monitors
├── Fingerstick glucose → treat hypoglycemia
├── Thiamine 100 mg IV (if malnutrition/alcohol suspected)
└── Labs: glucose, electrolytes, ASM levels, toxicology

TIME 5-20 MIN: FIRST-LINE (Benzodiazepines)
├── OPTION 1: IV Lorazepam 0.1 mg/kg (max 4 mg/dose)
│   └── May repeat x1 in 5-10 min
├── OPTION 2: IM Midazolam 10 mg (>40 kg) or 5 mg (13-40 kg)
│   └── Preferred if no IV access
├── OPTION 3: IV Diazepam 0.15-0.2 mg/kg (max 10 mg/dose)
│   └── May repeat x1
└── OPTION 4: Rectal Diazepam 0.2-0.5 mg/kg (max 20 mg) if no IV/IM

TIME 20-40 MIN: SECOND-LINE (Established SE)
├── If seizures continue after adequate benzodiazepine:
│
├── OPTION 1: Fosphenytoin 20 mg PE/kg IV (max 150 mg PE/min)
│   ├── Cardiac monitoring required
│   └── Avoid in known cardiac disease
│
├── OPTION 2: Valproate 40 mg/kg IV (max 3000 mg; rate 3-6 mg/kg/min)
│   ├── Avoid in pregnancy, liver disease
│   └── Preferred in generalized epilepsy
│
├── OPTION 3: Levetiracetam 60 mg/kg IV (max 4500 mg; over 15 min)
│   ├── Safe in cardiac, hepatic disease
│   └── Preferred in neonates with cardiac disorders
│
└── OPTION 4: Phenobarbital 15-20 mg/kg IV (if above unavailable)
    └── Respiratory depression risk

TIME 40-60 MIN: REFRACTORY SE (Third-Line)
├── Repeat second-line agent at 50% dose OR
├── Add different second-line agent OR
└── Proceed to anesthetic therapy:
    ├── Midazolam infusion: 0.2 mg/kg bolus → 0.1-2 mg/kg/hr
    ├── Propofol: 2 mg/kg bolus → 2-5 mg/kg/hr
    ├── Pentobarbital: 5-15 mg/kg → 0.5-3 mg/kg/hr
    └── ICU admission, continuous EEG monitoring required

>60 MIN: SUPER-REFRACTORY SE
├── Continue anesthetic infusion with EEG monitoring
├── Target burst-suppression for 24-48 hours
├── Add maintenance ASMs
├── Consider: ketamine, inhaled anesthetics, immunotherapy
└── Investigate underlying etiology
```

---

## 5.3 First-Line Benzodiazepine Dosing

| Agent | Route | Dose | Max Dose | Notes |
|-------|-------|------|----------|-------|
| **Lorazepam** | IV | 0.1 mg/kg | 4 mg/dose | First choice if IV available |
| **Midazolam** | IM | 0.2 mg/kg | 10 mg | Best if no IV access |
| **Midazolam** | Intranasal | 0.2 mg/kg | 10 mg | Alternative to IM |
| **Midazolam** | Buccal | 0.5 mg/kg | 10 mg | Alternative in children |
| **Diazepam** | IV | 0.15-0.2 mg/kg | 10 mg | Shorter duration than lorazepam |
| **Diazepam** | Rectal | 0.2-0.5 mg/kg | 20 mg | If no IV/IM access |

---

## 5.4 Second-Line Agent Comparison

### ESETT Trial Key Findings (2020)

The Established Status Epilepticus Treatment Trial demonstrated:

| Agent | Dose | Seizure Cessation | Conclusion |
|-------|------|-------------------|------------|
| Fosphenytoin | 20 mg PE/kg | 45% | No significant difference |
| Valproate | 40 mg/kg | 46% | between the three agents |
| Levetiracetam | 60 mg/kg | 47% | for second-line treatment |

> **Clinical Implication:** Choice among these three agents can be based on patient-specific factors (comorbidities, current ASMs, side effect profile).

### Second-Line Agent Selection Guide

| Agent | Preferred When | Avoid When |
|-------|---------------|------------|
| **Fosphenytoin** | Need rapid loading | Cardiac disease, hypotension |
| **Valproate** | Generalized epilepsy, unknown seizure type | Pregnancy, liver disease, mitochondrial disease |
| **Levetiracetam** | Cardiac disease, hepatic impairment, pregnancy | Already on high-dose LEV |
| **Phenobarbital** | Other agents unavailable | Need to avoid respiratory depression |

---

## 5.5 Pediatric Status Epilepticus

| Time | Treatment | Dose |
|------|-----------|------|
| 0-5 min | Stabilization | ABCs, glucose, access |
| 5-10 min | Lorazepam IV | 0.1 mg/kg (max 4 mg) |
| | OR Midazolam IM | 0.2 mg/kg (max 10 mg) |
| | OR Diazepam rectal | 0.5 mg/kg (max 20 mg) |
| 10-20 min | Repeat benzodiazepine | Same dose x1 |
| 20-40 min | Fosphenytoin | 20 mg PE/kg |
| | OR Valproate | 40 mg/kg |
| | OR Levetiracetam | 60 mg/kg |
| | OR Phenobarbital | 20 mg/kg |
| >40 min | Anesthetic therapy | ICU, continuous EEG |

---

## 5.6 Neonatal Status Epilepticus (ILAE 2023)

| Line | Agent | Dose | Notes |
|------|-------|------|-------|
| **First-line** | Phenobarbital | 20-40 mg/kg IV | Preferred regardless of etiology |
| **First-line (channelopathy)** | Phenytoin or Carbamazepine | Standard doses | If channelopathy suspected |
| **Second-line** | Phenytoin | 20 mg/kg IV | - |
| | Levetiracetam | 40-60 mg/kg IV | Preferred if cardiac disorder |
| | Midazolam | 0.15 mg/kg then infusion | - |
| | Lidocaine | 2 mg/kg then infusion | Avoid if cardiac issues |

---

## 5.7 Refractory SE Management

### Anesthetic Agents

| Agent | Loading Dose | Maintenance | Considerations |
|-------|--------------|-------------|----------------|
| **Midazolam** | 0.2 mg/kg | 0.1-2 mg/kg/hr | Tachyphylaxis common |
| **Propofol** | 2 mg/kg | 2-5 mg/kg/hr | Propofol infusion syndrome risk |
| **Pentobarbital** | 5-15 mg/kg | 0.5-3 mg/kg/hr | Longest duration; hypotension common |
| **Ketamine** | 1-2 mg/kg | 1-5 mg/kg/hr | Consider if others fail |

### Requirements for Anesthetic Therapy

- ICU admission
- Continuous EEG monitoring
- Mechanical ventilation
- Vasopressor support often needed
- Target: burst-suppression for 24-48 hours

---

## 5.8 Non-Convulsive Status Epilepticus (NCSE)

### Diagnosis
- EEG required for diagnosis
- Consider in any patient with unexplained altered mental status

### Treatment
- Same approach as convulsive SE
- May be less aggressive if patient stable
- Benzodiazepine trial can be diagnostic and therapeutic

---

[← Previous: Special Populations](04-special-populations.md) | [Back to Main](../README.md) | [Next: Drug Interactions →](06-drug-interactions.md)
